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The coronavirus disease 2019 (COVID-19) is associ-
ated with acute kidney injury (AKI) [1]. Additionally, 
early observations in China showed a high prevalence of 
proteinuria and hematuria in patients infected by SARS-
CoV-2. These findings have since been confirmed in other 
countries. Proteinuria might result from a proximal tubular 
dysfunction. COVID-19-induced AKI and proteinuria have 
been associated with poor short-term outcomes in hospital-
ized patients [2, 3]. However, the middle- and long- term 
consequences of SARS-CoV-2 infection on kidney function 
remain unknown. In the present observational single-center 
study, we report the follow-up (F-U) of both proteinuria and 
estimated glomerular filtration rate (eGFR) in COVID-19 
patients post hospital discharge [3]. 
All data were anonymized and the study had been 
approved by the Ethics Committee of ULiège Academic 
Hospital.
Patients older than 18 years of age admitted to Liège Aca-
demic Hospital between March 28th and April 30th, 2020 
with PCR-confirmed COVID-19, for whom data concern-
ing total proteinuria and/or urine α1-microglobulin were 
available were included in our study. A detailed descrip-
tion of the methodology has been previously published 
[3]. Briefly, serum creatinine and total proteinuria before 
COVID-19 were also collected when available. Total pro-
teinuria (expressed in mg/g of urine creatinine), urine α1-
microglobulin and β2-microglobulin were determined on 
a random spot. Proteinuria was staged according to the 
KDIGO (Kidney Disease Improving Global Outcomes). 
Urine α1-microglobulin was expressed in mg/g of urine cre-
atinine with a pathological threshold at > 15 mg/g. Urine 
β2-microglobulin was expressed in mg/L, with a pathologi-
cal threshold at > 0.19 mg/L. Hematuria was defined by the 
presence of more than 10 red blood cells per field. AKI 
during hospitalization (Hosp) was based on the KDIGO 
definition (after considering the serum level of creatinine at 
admission as the baseline value). Decreased kidney function 
was based on the CKD-Epidemiology equation (CKD-EPI) 
and using an age-calibrated definition. The same parameters 
were then followed after hospital discharge until August 
28th, 2020 in the context of a global health follow-up of 
hospitalized COVID-19 patients established by the hospital. 
Data are expressed as median with quartiles. Comparison 
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of independent and paired groups were performed using the 
Mann–Whitney U/Chi-square tests and Wilcoxon signed 
rank test/McNemar tests, respectively [3].
We included 153 hospitalized COVID-19 patients for 
whom urine data were available after a median period of 3 
(2; 5) days post admission (Hosp). Among the 153 patients, 
30 patients died (mortality rate of 19.6%). Of the 123 sur-
vivors, follow-up (F-U) urine analyses were available for 
72 patients (58.5%) (Flow chart in Supplementary Figure 
S1). The median period between the day of hospital dis-
charge and the last day of follow-up was 51 (19; 93) days. 
The median age of our 72-patient cohort was 64 (58–75) 
years old, with a M/F gender ratio of 37% (Supplementary 
Table S1). Median proteinuria levels (n = 72) at Hosp and 
F-U were 419 (239; 748) and 79 (47; 129) mg/g, respectively 
(p < 0.0001) (Table 1). During hospitalization, 15% (n = 11) 
had category 1 proteinuria, 43% (n = 31) had category 2 
and 42% (n = 30) had category 3. At F-U, 83% (n = 60) had 
category 1 proteinuria, 11% (n = 8) had category 2 and 6% 
(n = 4) had category 3. Of important note, 2 of these latter 
4 patients already had proteinuria prior to COVID-19, in 
the context of chronic uropathy (n = 1), diabetic nephropa-
thy (n = 1), and one patient had a rheumatological disorder 
treated by cyclosporine and maintained by methotrexate. 
At Hosp and F-U, the median concentrations of urinary α1-
microglobulin (n = 66) were 50 (25; 81) and 8 (0; 19) mg/g, 
respectively (p < 0.0001). The α1-microglobulin concentra-
tion was higher than 15 mg/g in 88% and 29% of patients at 
Hosp and F-U, respectively (Table 1). At Hosp and F-U, the 
median concentrations of urinary β2-microglobulin (n = 60) 
were 0.92 (0.41; 4.52) and 0.00 (0.00; 0.00) mg/L, respec-
tively (p < 0.0001). Urine β2-microglobulin was higher than 
0.19 mg/L in 82% and 13% of patients at Hosp and F-U, 
respectively. Data on hematuria were available at F-U in 51 
patients. At Hosp and F-U, 19% and 12% had hematuria, 
respectively (ns).
Hosp eGFR was lower than F-U eGFR: 81 (62; 92) versus 
87 (66; 98) mL/min/1.73m2 (p = 0.0222). Still, decreased 
renal function was observed in 10/72 (14%) patients at 
F-U compared to Hosp values. Among these 10 patients, 
5 already presented with decreased renal function before 
COVID-19. In the remaining 5 patients with normal renal 
function before COVID-19, 4 developed category 3 AKI 
during hospitalization and 3 transiently required renal 
replacement therapy (RRT). Note that dialysis was with-
drawn before hospital discharge in all 3 patients who 
required RRT during hospitalization.
Our F-U observations suggest that, although COVID-19 
is associated with a high prevalence of tubular proteinu-
ria and AKI, most patients (~ 80%) recover statu quo ante 
within ~ a month post hospital discharge. Patients with per-
sistent proteinuria at F-U already had previous clinical con-
ditions favoring chronic proteinuria and/or suffered from the 
most severe AKI. The statistically significant, but probably 
not clinically relevant, difference between eGFR at Hosp 
and F-U remains in the range of normality. Patients with 
COVID-19 often presented with fever and gastrointesti-
nal symptoms that may account for volume depletion and 
explain the slightly lower level of eGFR at Hosp compared 
to F-U. The main limitation of our study is the retrospective 
analysis of the data. Moreover, although we lack measure-
ments regarding urine albumin (not reimbursed by the Bel-
gian health system), protein immunofixation was available in 
more than 50% of patients at Hosp and F-U and clearly dem-
onstrated a pattern of mixed proteinuria. Finally, the design 
of the current study did not allow us to formally distinguish 
acute tubular necrosis caused by septic conditions, potential 
toxicity of drugs or contrast agents during hospitalization or 
Table 1  Renal parameters at the 
time of urine analysis during 















Decreased GFR (%) (age adapted definition) 20.8 14 ns
Decreased GFR (KDIGO) 23 18 ns
Proteinuria (mg/g) (n = 72) 419 (239;748) 79 (47;129)  < 0.0001
Proteinuria
Category 1 (%) 15 83
Category 2 (%) 43 11
Category 3 (%) 42 6
Urine α1-microglobulin (mg/g) (n = 66) 50 (25;82) 8 (0;19)  < 0.0001
Urine α1-microglobulin > 15 mg/g (%) 88 29
Urine β2-microglobulin (n = 60) (mg/L) 0.92 (0.41;4.52) 0.00 (0.00;0.00)  < 0.0001
Urine β2-microglobulin > 0.19 mg/L (%) 82 13
Hematuria (> 10 per field) (%) (n = 51) 19 12 ns
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cytopathic lesions caused by SARS-CoV-2 itself, but the fact 
is that long-term consequences seem limited.
The present study confirms first reports suggesting that 
long-term renal sequelae of COVID-19 appear uncommon 
[4, 5]. Similarly to other severe infectious diseases, a specific 
follow-up by nephrologists is recommended for survivors 
of COVID-19 who developed severe AKI and/or heavy pro-
teinuria (~ nephrotic range). These reassuring data need to 
be confirmed in larger cohorts.
Supplementary Information The online version contains supplemen-
tary material available at https:// doi. org/ 10. 1007/ s40620- 021- 01075-1.
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